Primerica Inc
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Primerica Inc (PRI). It shows which part of the business is growing — and which one is holding it back.
Revenue by business segment
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Term Life Insurance Segment [Member] | $1.38B 62.4% | $1.54B 56.8% · +11.3% | $1.64B 61.6% · +6.3% | $1.69B 61.6% · +3.5% | $1.77B 57.2% · +4.4% | $1.82B 55.3% · +2.9% |
| Investment and Savings Products Segment [Member] | $718.9M 32.4% | $941.8M 34.8% · +31.0% | $863.4M 32.5% · -8.3% | $865.3M 31.5% · +0.2% | $1.06B 34.2% · +22.1% | $1.25B 37.9% · +18.1% |
| Corporate and Other Distributed Products Segment [Member] | $115.9M 5.2% | $168.2M 6.2% · +45.2% | $158.1M 5.9% · -6.1% | $190.2M 6.9% · +20.3% | $264.2M 8.6% · +38.9% | $223.7M 6.8% · -15.3% |
| Senior Health Segment [Member] | – | $60.4M 2.2% | – | – | – | – |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Revenue by region
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| United States [Member] | $1.90B 85.5% | $2.31B 85.3% · +21.9% | $2.29B 86.3% · -0.8% | $2.40B 87.2% · +4.6% | $2.69B 87.2% · +12.4% | $2.85B 86.6% · +5.8% |
| Canada [Member] | $321.8M 14.5% | $398.7M 14.7% · +23.9% | $365.0M 13.7% · -8.4% | $351.7M 12.8% · -3.6% | $394.8M 12.8% · +12.2% | $440.8M 13.4% · +11.6% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: August 11, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.